Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

159.60
Net Asset Value
-0.10%
1 Day
+3.80%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.81%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Performance

1 month-2.55% 3 years-0.53%
3 months+8.78% 5 years+17.43%
1 year+11.82% Since inception+18.89%
Data through --

Peer Comparisonvs. Health

 FTDZXCategory
Performance 5-yr return+17.43%+17.28%
Expense ratio0.81%1.31%
Risk 5 year sharpe ratio0.801.11
Net assets$1.5B$3.2B
Average market cap$8.0B$9.5B
Average P/E--22.6
Portfolio turnover34%34%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 20 Years
Minimal initial investment$100,000.00
Minimum IRA investment--

Holdings

U.S. stock94.92%
International stock2.77%
Cash1.75%
Fixed income0.56%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
CELG Celgene7.75%
ALXN Alexion Pharmaceuticals Inc7.57%
BIIB Biogen5.34%
VRTX Vertex Pharmaceuticals Inc4.35%
ILMN Illumina Inc4.32%
REGN Regeneron Pharmaceuticals4.24%
NBIX Neurocrine Biosciences Inc4.07%
INCY Incyte Corp3.71%
CLVS Clovis Oncology Inc3.36%
GILD Gilead Sciences3.32%